Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma

BACKGROUND: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma (DLBCL) by ~20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas, is the target for rituximab. The goal of our study was to examine polymorphism in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Huirong, Jin, Xuan, Ding, Ning, Fu, Zhiying, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686705/
https://www.ncbi.nlm.nih.gov/pubmed/23758737
http://dx.doi.org/10.1186/1475-2867-13-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686705/
https://www.ncbi.nlm.nih.gov/pubmed/23758737
http://dx.doi.org/10.1186/1475-2867-13-58

Ejemplares similares